Benchmark competitiveness and generalization are not equivalent: a critical commentary on HybridSP.

Area of Science:

• Computational chemistry
• Drug discovery
• Bioinformatics

Background:

• The HybridSP model has shown promising benchmark performance for protein-ligand scoring.
• Assessing the generalization capabilities of computational models is crucial for reliable predictions.

Purpose of the Study:

• To critically evaluate the generalization claims of the HybridSP model.
• To advocate for more rigorous validation methods in computational drug discovery.

Main Methods:

• Analysis of benchmark performance metrics.
• Examination of model behavior on bias-reduced and challenging datasets.
• Comparison of scoring pipelines and underlying tasks.

Main Results:

• Benchmark performance of HybridSP may be inflated due to coefficient tuning and cross-pipeline comparisons.
• Performance degradation on more challenging datasets indicates limited transferability.
• Existing validation may not fully capture robust generalization.

Conclusions:

• Strong benchmark results for HybridSP should be interpreted cautiously regarding generalization.
• The model's transferability is potentially limited, as suggested by performance drops.
• Stricter validation frameworks are essential for protein-ligand scoring models to support generalization claims.